US2002086818A1PendingUtilityA1

Combination therapy including 9-nitro-20(S)-camptothecin and 5-fluorouracil

59
Priority: Oct 15, 1999Filed: Feb 11, 2002Published: Jul 4, 2002
Est. expiryOct 15, 2019(expired)· nominal 20-yr term from priority
Inventors:Joseph Rubinfeld
A61K 31/70A61P 35/00A61K 31/4745A61K 31/44A61K 45/06
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating diseases comprises delivering to a patient in need of treatment a therapeutically effective amount of 20(S)-camptothecin, an analog of 20(S)-camptothecin, or a derivative of 20(S)-camptothecin in combination with an effective amount of at least one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic or vinca alkaloid.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A pharmaceutical composition having therapeutic synergy comprising: 
 20(S)-camptothecin, an analog of 20(S)-camptothecin, or a derivative of 20(S)-camptothecin; and    at least one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic or vinca alkaloid.    
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein the alkylating agent is cyclophosphamide, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine.  
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein the antimetabolite is 5-fluorouracil, cytarabine or a folic acid analog.  
     
     
         4 . A pharmaceutical composition according to  claim 1 , wherein the antibiotic is daunorubicine, doxorubicin, bleomycin or mitomycin.  
     
     
         5 . A pharmaceutical composition according to  claim 1 , wherein the vinca alkaloid is vinblastine, vincristine, or their synthetic analogues.  
     
     
         6 . A pharmaceutical composition according to  claim 1 , wherein the epidophyllotoxin is etoposide or teniposide.  
     
     
         7 . A pharmaceutical composition according to  claim 1 , wherein said composition is useful in the treatment of neoplastic diseases.  
     
     
         8 . A pharmaceutical composition according to  claim 1 , wherein the 20(S)-camptothecin is 9-amino-20(S)-camptothecin.  
     
     
         9 . A pharmaceutical composition according to  claim 1 , wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.  
     
     
         10 . A method for treating disease comprising: 
 delivering to a patient in need of treatment a therapeutically effective amount of 20(S)-camptothecin, an analog of 20(S)-camptothecin, or a derivative of 20(S)-camptothecin in combination with an effective amount of at least one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic or vinca alkaloid.    
     
     
         11 . A method according to  claim 10 , wherein the alkylating agent is cyclophosphamide, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine.  
     
     
         12 . A method according to  claim 10 , wherein the antimetabolite is 5-fluorouracil, cytarabine or a folic acid analog.  
     
     
         13 . A method according to  claim 10 , wherein the antibiotic is daunorubicine, doxorubicin, bleomycin or mitomycin.  
     
     
         14 . A method according to  claim 10 , wherein the vinca alkaloid is vinblastine, vincristine, or their synthetic analogues.  
     
     
         15 . A method according to  claim 10 , wherein the epidophyllotoxin is etoposide or teniposide.  
     
     
         16 . A method according to  claim 10 , wherein said composition is useful in the treatment of neoplastic diseases.  
     
     
         17 . A method according to  claim 10 . wherein the 20(S)-camptothecin is 9-amino-20(S)-camptothecin.  
     
     
         18 . A method according to  claim 10 , wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

Join the waitlist — get patent alerts

Track US2002086818A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.